University of Texas MD Anderson Cancer Center

Houston, Texas
Professor, Department of Cancer Biology,
Division of Basic Science Research


Dr. Ron DePinho, the recipient of the National Foundation for Cancer Research 2009 Szent-Gyorgyi Prize for Progress in Cancer Research, is working with other scientists on a new drug to target a major signaling protein in over 50% of cancers. The signaling molecule, STAT3, has an integral role in formation of tumors (tumorigenesis) and suppression of our immune system. STAT3 activates transcription – or expression of genes – and therefore controls networks of genes for multiple cellular processes, including proliferation, survival, angiogenesis, metastasis, invasion, and immune escape.

Hyperactivation of STAT3 has been reported in many types of tumors, including head-and neck, brain, breast, liver, lung, kidney, pancreas, prostate, and ovary cancer. STAT3’s key position in cancer signaling as well as in inflammation and fibrosis pathways have been the focus of numerous research and clinical initiatives by the research community to develop effective drugs that target STAT3. Deemed an undruggable molecule, there have been difficulties in developing targeted therapies to STAT3 which include designing stable molecules, creating molecules that can access the inside of cells (membrane permeability) and achieving the optimal dose in tumors to halt tumor growth.

Using computer-based drug screening of hundreds of thousands of compounds from chemical libraries, the scientists have identified several compounds that inhibit STAT3 protein in complex tumor models of various cancer types.

With NFCR support, their efforts have led to a promising therapeutic now being commercialized by the AIM-HI Translational Research Initiative. To learn more, click here.


Dr. Ronald A. DePinho was the fourth president of The University of Texas MD Anderson Cancer Center, serving from 2012 to 2018 prior to his current position as Professor, Department of Cancer Biology, Division of Basic Science Research, and the Harry Graves Burkhart III Distinguished University Chair in Cancer Biology. Dr. DePinho was a professor of Medicine (Genetics) at Harvard Medical School from 1998 to 2011. He received his M.D. from Albert Einstein College of Medicine in 1981 and began his academic career where he rose to Professor, Department of Departments of Microbiology & Immunology, and Medicine.

Dr. DePinho is an elected member of the National Academy of Medicine; National Academy of Science; Foreign Member, Royal Academy of Science, Portugal; among other memberships in prestigious institutions. In addition to the Szent-Gyorgyi Prize for Progress in Cancer Research, he has received numerous awards including the Biomedicum Helsinki Medal and Lecture, Harvey Society Lecture, and the Prize for Scientific Excellence in Medicine, American Italian Cancer Foundation. His community service includes Member, Steering Committee, National Cancer Institute, Co-Chair, External Advisory Board, The Human Cancer Genome Atlas Project, and numerous cancer society memberships. Dr. DePinho is the author of over 400 publications.

Related Content

Breast Cancer Survivors Need to Take Actions to Reduce Their Increased Risk of Cardiovascular Disease

New Treatment & Renewed Hope for Triple-negative Breast Cancer Patients

Nut-Consumption and Breast Cancer Survival

Breast cancer is the most common type of cancer among women in the world and, although less common, it can also affect men. An estimated 284,200 new breast cancer cases will be diagnosed in the United States this year, and tragically an estimated 44,130 deaths will occur. While screening and treatment options have become more advanced, it is still important for women to proactively reduce breast cancer risk factors. Thankfully, a team of renowned researchers recently discovered that breast cancer prevention could be as simple as eating a handful of trail mix. Connecting the Dots Researchers from Vanderbilt University Medical Center and the Shanghai Municipal Center of Disease Control and Prevention concluded that nut consumption appeared to be associated with higher survival rates among long-term breast cancer survivors. The researchers suggest emphasizing this finding as a modifiable lifestyle factor in survivor guidelines. The team came to this conclusion after analyzing associations of peanut and tree nut consumption with overall survival (OS) and disease-free survival (DFS) among 3,449 long-term breast cancer survivors aged 20 to 75 years who participated in the Shanghai Breast Cancer Survival Study. Of these participants, 3,148 women reported nut consumption, and 301 women reported no nut consumption. The researchers obtained a detailed dietary assessment, which the women completed at the 5-year post-diagnosis follow-up interview between October 2007 and October 2011. The team converted the consumption of nuts into grams per week and calculated total nut consumption as the sum of intake from peanuts, walnuts, and other nuts. Here’s what they found: Participants who consumed nuts regularly had higher rates of OS and DFS (by 4.7% and 7.9%, respectively) 10 years after diagnosis. There were positive associations of nut consumption with OS and DFS after a dose-response pattern for participants with greater-than-median (17.32 g per week) nut intake compared with non-consumers. The team explained that nuts are a common nutrient-dense food seen in healthy diets. As such, several studies have found nuts to be associated with reduced mortality, particularly mortality due to cardiovascular diseases, in the general population. Previously we knew little on whether the health benefits of nut intake extended to breast cancer survivors, particularly regarding the DFS. The goal of this study was to address this knowledge gap. Which nuts should you be eating? While the study mentions peanuts and walnuts by name, there are a variety of nuts that can offer cancer-fighting benefits. Here’s what experts at National Foundation for Cancer Research (NFCR) have to say: Brazil nuts contain the richest source of natural selenium, a nutrient that may play a critical role in reducing the risk of certain cancers Walnuts have pedunculagin, a tannin that the body metabolizes into urolithins. Urolithins are compounds that bind to estrogen receptors and may play a role in preventing breast cancer. Related NFCR-Supported Research NFCR-funded researchers also point out that while eating cancer-fighting foods is a great step, there are other essential factors to include to prevent various cancers – including breast cancer. Exercise and regular screening (where applicable) are vital in preventing and treating cancer. Recently, NFCR-funded scientist Dr. Rakesh Jain and his team at Massachusetts General […]